Evidence map›Paper›PMID 37381164›Full record

ArticleClinical and translational medicine2023

Development of immune-related cell-based machine learning for disease progression and prognosis of alcoholic liver disease.

Xu Zhang, Xuezhe Feng, Qian Huai, Cheng Zhu, Yingyin Sun, Xiaolei Li, Hanren Dai, Honglin Wang, Hua Wang

Abstract readLetter
In one paragraph

Article in Clinical and translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. A CLRN3-Based CD8Biomolecules · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xu ZhangDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xuezhe FengDepartment of Stomatology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Qian HuaiDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cheng ZhuDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yingyin SunDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiaolei LiDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hanren DaiDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Honglin WangDepartment of Microscopic Orthopedics, the Hefei Second People's Hospital & Hefei Affiliated Hospital of Anhui Medical University, Hefei, China.
Hua WangDepartment of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID https://orcid.org/0000-0002-2605-5697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Liver Diseases, AlcoholicDisease ProgressionHumansPrognosis

Identifiers

PMID37381164
PMCPMC10307989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.